We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $962M
1-Year Est. Return 524.64%
This Fund
S&P 500
This Quarter Est. Return
+59.01%
1 Year Est. Return
+524.64%
3 Year Est. Return
+2,765.44%
5 Year Est. Return
+10,523.08%
10 Year Est. Return
–
AUM
$720M
AUM Growth
-$21.6M
Cap. Flow
-$156M
Cap. Flow %
-21.71%
Top 10 Hldgs %
49.7%
Holding
103
New
21
Increased
18
Reduced
27
Closed
35

Top Buys

Rank Stock Value
1
CELC icon
Celcuity
CELC
+$23.5M
2
IMNM icon
Immunome
IMNM
+$19.8M
3
KALV
KalVista Pharmaceuticals
KALV
+$14.1M
4
COGT icon
Cogent Biosciences
COGT
+$12.1M
5
PFE icon
Pfizer
PFE
+$10.6M

Top Sells

Rank Stock Value
1
RNAM
Avidity Biosciences
RNAM
+$36.8M
2
AKRO
Akero Therapeutics
AKRO
+$30.6M
3
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$24.8M
4
INSM icon
Insmed
INSM
+$24.7M
5
CDTX
Cidara Therapeutics
CDTX
+$21.2M

Sector Composition

Rank Sector Weight
1 Healthcare 95.99%
2 Miscellaneous 4.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABVX
1
Abivax
ABVX
$10.4B
$56.9M 7.91%
422,193
-117,511
-22% -$12.8M
COGT icon
2
Cogent Biosciences
COGT
$6.12B
$44.2M 6.14%
1,245,254
+430,179
+53% +$12.1M
URGN icon
3
UroGen Pharma
URGN
$2.14B
$40.7M 5.66%
1,738,821
+161,538
+10% +$3.5M
KALV
4
DELISTED
KalVista Pharmaceuticals
KALV
$39.2M 5.44%
2,427,118
+1,063,740
+78% +$14.1M
CELC icon
5
Celcuity
CELC
$4.55B
$37.4M 5.2%
375,132
+286,446
+323% +$23.5M
NUVL
6
DELISTED
Nuvalent
NUVL
$31.3M 4.35%
311,430
-60,870
-16% -$6M
DNTH icon
7
Dianthus Therapeutics
DNTH
$6.1B
$30.9M 4.29%
750,136
+75,170
+11% +$2.91M
KOD icon
8
Kodiak Sciences
KOD
$2.2B
$28.6M 3.97%
1,023,122
+23,122
+2% +$474K
PRAX icon
9
Praxis Precision Medicines
PRAX
$9.84B
$24.3M 3.38%
82,465
+31,255
+61% +$5.82M
IMNM icon
10
Immunome
IMNM
$3.05B
$24.2M 3.36%
+1,126,210
New +$19.8M
GUTS icon
11
Fractyl Health
GUTS
$109M
$21.6M 3.01%
9,840,041
-759,959
-7% -$1.22M
QURE icon
12
CALL
uniQure
QURE
$3.17B
$17.2M 2.4%
+720,800
New +$27.8M
GLUE icon
13
Monte Rosa Therapeutics
GLUE
$1.22B
$16.1M 2.24%
1,029,066
+334,124
+48% +$4.5M
VCYT icon
14
Veracyte
VCYT
$3.41B
$15.1M 2.09%
357,558
+121,767
+52% +$4.91M
CGON icon
15
CG Oncology
CGON
$6.51B
$15M 2.08%
361,158
-277,188
-43% -$11.5M
RYTM icon
16
Rhythm Pharmaceuticals
RYTM
$7.01B
$14.6M 2.02%
135,950
-234,046
-63% -$24.8M
SNDX icon
17
Syndax Pharmaceuticals
SNDX
$1.78B
$13.5M 1.88%
642,899
+179,191
+39% +$3.13M
BIIB icon
18
Biogen
BIIB
$31.4B
$13.3M 1.84%
75,412
-5,007
-6% -$818K
INSM icon
19
Insmed
INSM
$27.3B
$12.4M 1.72%
71,256
-135,392
-66% -$24.7M
CNTA
20
DELISTED
Centessa Pharmaceuticals
CNTA
$11.5M 1.59%
458,203
+316,965
+224% +$8.03M
VRDN icon
21
Viridian Therapeutics
VRDN
$2.62B
$10.8M 1.51%
348,569
+89,060
+34% +$2.44M
ASND icon
22
Ascendis Pharma A/S
ASND
$17.7B
$10.5M 1.46%
49,228
-4,326
-8% -$893K
PFE icon
23
Pfizer
PFE
$158B
$10.4M 1.45%
+419,134
New +$10.6M
BNTC icon
24
Benitec Biopharma
BNTC
$437M
$9.86M 1.37%
731,717
+455,450
+165% +$6.3M
AVTX icon
25
Avalo Therapeutics
AVTX
$1.06B
$9.52M 1.32%
524,436
-196,486
-27% -$3.32M
1
2 3 4 5

Similar funds

LGP
Leonard Green & Partners Los Angeles, California $962M AUM 35.11% 1-Year Est. Return
PL
Parthenon LLC Louisville, Kentucky $962M AUM 27.46% 1-Year Est. Return
LAM
L2 Asset Management Wayland, Massachusetts $963M AUM 38.06% 1-Year Est. Return
ACP
Aviance Capital Partners Naples, Florida $963M AUM 32.56% 1-Year Est. Return
GIG
Goodnow Investment Group Darien, Connecticut $964M AUM 2.51% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
BEAM
Baker Ellis Asset Management Vancouver, Washington $964M AUM 39.24% 1-Year Est. Return
RAM
Ramirez Asset Management New York $960M AUM 30.25% 1-Year Est. Return

Silverarc Capital Management's Q4 2025 Portfolio in Review

As of Q4 2025, Silverarc Capital Management held 103 positions worth $720M, down 2.9% from $742M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Silverarc Capital Management withdrew a net $156M in Q4 2025, closing 35 positions and reducing 27 holdings. Its most notable exit was Avidity Biosciences, an estimated $36.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 93% a quarter earlier, followed by Miscellaneous.

Against the trend, Silverarc Capital Management opened a new position in Immunome worth $24.2M.

  • Silverarc Capital Management's largest Q4 2025 buy was Immunome: 1,126,210 shares worth $24.2M.
  • Silverarc Capital Management added most to Celcuity in Q4 2025, an estimated $23.5M increase.
  • Silverarc Capital Management's biggest Q4 2025 reduction was Rhythm Pharmaceuticals, cutting an estimated $24.8M.
  • Silverarc Capital Management fully exited Avidity Biosciences in Q4 2025, selling an estimated $36.8M.
  • Silverarc Capital Management's ten largest holdings make up 50% of its $720M portfolio in Q4 2025.
  • Silverarc Capital Management opened 21 new positions and closed 35 in Q4 2025.
  • Silverarc Capital Management's portfolio value fell 2.9% quarter-over-quarter to $720M.

Based on Silverarc Capital Management's 13F filing for Q4 2025, filed 12 Feb 2026.